{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:15:00Z","timestamp":1788052500750,"version":"build-2784847793"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119158","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:35:46Z","timestamp":1783956946000},"page":"119158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Unsymmetrical bisacridines as anticancer drug candidates: structure\u2013metabolism\u2013activity relationships and design principles"],"prefix":"10.1016","volume":"318","author":[{"given":"Dominika Zuzanna","family":"Rafalska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Paku\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Borzyszkowska-Bukowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1853-9277","authenticated-orcid":false,"given":"Agnieszka","family":"Pot\u0119ga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119158_bib1","series-title":"Heterocyclic Compounds: the Acridines. Their Preparation, Physical, Chemical, and Biological Properties and Uses","first-page":"927","author":"Foss","year":"1967"},{"key":"10.1016\/j.ejmech.2026.119158_bib2","series-title":"Synthesis of Essential Drugs","first-page":"559","article-title":"Drugs for treating protozoan infections","author":"Vardanyan","year":"2006"},{"key":"10.1016\/j.ejmech.2026.119158_bib3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/bs.aihch.2015.04.004","article-title":"Recent advances in the chemistry of acridines","volume":"115","author":"Schmidt","year":"2015","journal-title":"Adv. Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2026.119158_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/47.1.1","article-title":"Acridine \u2013 a neglected antibacterial chromophore","volume":"47","author":"Wainwright","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2026.119158_bib5","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1021\/jm970232h","article-title":"Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1\u2019-substituted 9-anilinoacridines","volume":"40","author":"Gamage","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119158_bib6","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1016\/j.bmcl.2004.07.015","article-title":"Synthesis of dimeric acridine derived antivirals","volume":"14","author":"Csuk","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119158_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/pathogens10020189","article-title":"Antifungal activity of capridine \u03b2 as a consequence of its biotransformation into metabolite affecting yeast topoisomerase II activity","volume":"10","author":"Gabriel","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.ejmech.2026.119158_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118174","article-title":"Bisacridine derivatives as effective eukaryotic topoisomerase II inhibitors","volume":"301","author":"Kondaka","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119158_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/187152007780058669","article-title":"Acridine and acridone derivatives, anticancer properties and synthetic methods: where are we now?","volume":"7","author":"Belmont","year":"2007","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119158_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/molecules28010193","article-title":"Acridine as an anti-tumour agent: a critical review","volume":"28","author":"Varakumar","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119158_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.dyepig.2021.109924","article-title":"Acridine-based fluorophores with improved lightfastness properties","volume":"197","author":"Baig Moghal","year":"2022","journal-title":"Dyes Pigments"},{"key":"10.1016\/j.ejmech.2026.119158_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00925","article-title":"Acridine orange: a review of novel applications for surgical cancer imaging and therapy","volume":"9","author":"Byvaltsev","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119158_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0143-7208(00)00025-5","article-title":"Optical thin film polymeric sensors for the determination of aqueous chloride, bromide and iodide ions at high pH, based on the quenching of fluorescence of two acridinium dyes","volume":"45","author":"Geddes","year":"2000","journal-title":"Dyes Pigments"},{"key":"10.1016\/j.ejmech.2026.119158_bib14","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1021\/jm00245a013","article-title":"Potential antitumor agents. 16. 4'-(Acridin-9-ylamino)methanesulfonanilides","volume":"18","author":"Cain","year":"1975","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119158_bib15","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1021\/jm00234a012","article-title":"Potential antitumor agents. 20. Structure-activity-site relationships for the 4\u2019-(9-acridinylamino)alkanesulfonanilides","volume":"19","author":"Cain","year":"1976","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119158_bib16","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1021\/bi201159b","article-title":"Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions","volume":"51","author":"Ketron","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2026.119158_bib17","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.3390\/ijms160613023","article-title":"Synthesis, DNA binding, and antiproliferative activity of novel acridine-thiosemicarbazone derivatives","volume":"16","author":"de Almeida","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119158_bib18","first-page":"237","article-title":"Ledacrin - anticancerous medicine 1-nitro-9(3-dimethyloaminopropylamino)-acridine-2HCl-H2O, mater","volume":"8","author":"Led\u00f3chowski","year":"1976","journal-title":"Med. Pol."},{"key":"10.1016\/j.ejmech.2026.119158_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0306-3623(94)00143-B","article-title":"Nitracrine and its congeners\u2014an overview","volume":"26","author":"Gniazdowski","year":"1995","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119158_bib20","first-page":"68847u","article-title":"European patent application 0038572, 1-Nitro-9-hydroxyalkylaminoacridines or their salts","volume":"96","author":"Wysocka-Skrzela","year":"1982","journal-title":"Chem. Abstr."},{"key":"10.1016\/j.ejmech.2026.119158_bib21","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.lfs.2006.03.043","article-title":"Pre-clinical toxicology and pathology of 9-(2\u2019-hydroxyethylamino)-4-methyl-1-nitroacridine (C-1748), a novel anti-cancer agent in Male Beagle dogs","volume":"79","author":"Ashok","year":"2006","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2026.119158_bib22","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.4161\/cbt.6.10.4790","article-title":"Pre-clinical evaluation of 1-nitroacridine derived chemotherapeutic agent that has preferential cytotoxic activity towards prostate cancer","volume":"6","author":"Tadi","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejmech.2026.119158_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1021\/jm00163a009","article-title":"5-[(Aminoalkyl)amino]imidazo[4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents. Synthesis and biological activity","volume":"33","author":"Cholody","year":"1990","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119158_bib24","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1021\/jm00172a028","article-title":"8-Substituted 5-[(aminoalkyl)amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones as potential antineoplastic agents. Synthesis and biological activity","volume":"33","author":"Cholody","year":"1990","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119158_bib25","first-page":"415","article-title":"Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones","volume":"42","author":"Kusnierczyk","year":"1994","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.ejmech.2026.119158_bib26","first-page":"2094","article-title":"Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents","volume":"56","author":"Berger","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119158_bib27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.molstruc.2017.05.042","article-title":"Chemical structures and biological activities of bis- and tetrakis-acridine derivatives: a review","volume":"1146","author":"Nowak","year":"2017","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2026.119158_bib28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0005-2787(76)90291-4","article-title":"Diacridines: bifunctional intercalators. II. The biological effects of putrescine, spermidine and spermine diacridines on HeLa cells and on the L-1210 and P-388 leukemia cells","volume":"418","author":"Canellakis","year":"1976","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2026.119158_bib29","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1021\/jm00207a006","article-title":"Diacridines, bifunctional intercalators. Chemistry and antitumor activity","volume":"21","author":"Chen","year":"1978","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119158_bib30","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1139\/o78-159","article-title":"Bis-intercalative binding to DNA of novel bis(10-methyl)acridinium chlorides and its dependence on chain length of linker","volume":"56","author":"Lown","year":"1978","journal-title":"Can. J. Biochem."},{"key":"10.1016\/j.ejmech.2026.119158_bib31","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1021\/bi00566a026","article-title":"Effects of ring substituents and linker chains on the bifunctional intercalation of diacridines into deoxyribonucleic acid","volume":"19","author":"Wright","year":"1980","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2026.119158_bib32","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1432-1033.1989.tb14656.x","article-title":"Acridine dimers: influence of the intercalating ring and of the linking-chain nature on the equilibrium and kinetic DNA-binding parameters","volume":"180","author":"Markovits","year":"1989","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2026.119158_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0165-022X(03)00081-2","article-title":"A comparative study on the interaction of acridine and synthetic bis-acridine with G-quadruplex structure","volume":"57","author":"Nagesh","year":"2003","journal-title":"J. Biochem. Biophys. Methods"},{"key":"10.1016\/j.ejmech.2026.119158_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26157557","article-title":"Pro-apoptotic effects of unsymmetrical bisacridines in 3D pancreatic multicellular tumor spheroids","volume":"26","author":"Kurdyn","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119158_bib35","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0277-5379(82)90117-1","article-title":"Development and cross-resistance characteristics of a subline of P388 leukemia resistant to 4\u2032-(9-acridinylamino)-methanesulfon-m-anisidide","volume":"18","author":"Johnson","year":"1982","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119158_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112599","article-title":"Design, synthesis and high antitumor potential of new unsymmetrical bisacridine derivatives towards human solid tumors, specifically pancreatic cancers and their unique ability to stabilize DNA G-quadruplexes","volume":"204","author":"Paluszkiewicz","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119158_bib37","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.3390\/ijms23063061","article-title":"c-Myc protein level affected by unsymmetrical bisacridines influences apoptosis and senescence induced in HCT116 colorectal and H460 lung cancer cells","volume":"23","author":"Paw\u0142owska","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119158_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-30587-y","article-title":"The interactions of monomeric acridines and unsymmetrical bisacridines (UAs) with DNA duplexes: an insight provided by NMR and MD studies","volume":"13","author":"Laskowski","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119158_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102513","article-title":"The interactions of Pu22 G-quadruplex, derived from c-MYC promoter sequence, with antitumor acridine derivatives\u2014an NMR\/MD combined study","volume":"36","author":"Laskowski","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejmech.2026.119158_bib40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.18388\/abp.2000_4063","article-title":"The intercalation of imidazoacridinones into DNA induces conformational changes in their side chain","volume":"47","author":"Mazerski","year":"2000","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.ejmech.2026.119158_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/tx000081c","article-title":"Products of metabolic activation of the antitumor drug Ledakrin (Nitracrine) in vitro","volume":"14","author":"Gorlewska","year":"2001","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119158_bib42","doi-asserted-by":"crossref","first-page":"17276","DOI":"10.1021\/acsami.0c02621","article-title":"New unsymmetrical bisacridine derivatives noncovalently attached to quaternary quantum dots improve cancer therapy by enhancing cytotoxicity toward cancer cells and protecting normal cells","volume":"12","author":"Pilch","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejmech.2026.119158_bib43","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.3390\/molecules26206262","article-title":"The influence of antitumor unsymmetrical bisacridines on 3D cancer spheroids growth and viability","volume":"26","author":"Kulesza","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119158_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15010201","article-title":"pH-responsive drug delivery nanoplatforms as smart carriers of unsymmetrical bisacridines for targeted cancer therapy","volume":"15","author":"Pilch","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119158_bib45","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3390\/60300230","article-title":"Synthesis of acridine-based DNA bis-intercalating agents","volume":"6","author":"Moloney","year":"2001","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119158_bib46","doi-asserted-by":"crossref","first-page":"5622","DOI":"10.1093\/nar\/gki869","article-title":"Characterization of the bisintercalative DNA binding mode of a bifunctional platinum-acridine agent","volume":"33","author":"Choudhury","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.119158_bib47","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1021\/jm980687m","article-title":"Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents","volume":"42","author":"Gamage","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119158_bib48","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1021\/bi00263a023","article-title":"Interactions of some novel amide-linked bis(acridines) with deoxyribonucleic acid","volume":"21","author":"King","year":"1982","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2026.119158_bib49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0223-5234(02)01348-X","article-title":"Synthesis, cytotoxic activities and proposed mode of binding of a series of bis{[(9-oxo-9,10-dihydroacridine-4-carbonyl)amino]alkyl}alkylamines","volume":"37","author":"Bra\u00f1a","year":"2002","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119158_bib50","doi-asserted-by":"crossref","first-page":"9136","DOI":"10.1021\/acs.jmedchem.9b01917","article-title":"Syntheses and evaluation of new bisacridine derivatives for dual binding of G-quadruplex and i-motif in regulating oncogene c-myc expression","volume":"63","author":"Kuang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119158_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/ph14040317","article-title":"Metabolic profiles of new unsymmetrical bisacridine antitumor agents in electrochemical and enzymatic noncellular systems and in tumor cells","volume":"14","author":"Mieszkowska","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119158_bib52","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jpha.2021.03.014","article-title":"Novel insights into conjugation of antitumor-active unsymmetrical bisacridine C-2028 with glutathione: characteristics of non-enzymatic and glutathione S-transferase-mediated reactions","volume":"11","author":"Pot\u0119ga","year":"2021","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.ejmech.2026.119158_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29235582","article-title":"Unsymmetrical bisacridines' interactions with ABC transporters and their cellular impact on colon LS 174T and prostate DU 145 cancer cells","volume":"29","author":"Paw\u0142owska","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119158_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119158_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27133995","article-title":"Acid-base equilibrium and self-association in relation to high antitumor activity of selected unsymmetrical bisacridines established by extensive chemometric analysis","volume":"27","author":"Kosno","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119158_bib56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2026.119158_bib57","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/acs.chemrestox.5b00017","article-title":"Site of reactivity models predict molecular reactivity of diverse chemicals with glutathione","volume":"28","author":"Hughes","year":"2015","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119158_bib58","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1093\/bioinformatics\/btw350","article-title":"A simple model predicts UGT-mediated metabolism","volume":"32","author":"Dang","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejmech.2026.119158_bib59","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1021\/acs.chemrestox.6b00385","article-title":"Deep learning to predict the formation of quinone species in drug metabolism","volume":"30","author":"Hughes","year":"2017","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119158_bib60","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1021\/acs.jcim.9b00836","article-title":"The metabolic rainbow: deep learning Phase I metabolism in five colors","volume":"60","author":"Dang","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.119158_bib61","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.3390\/molecules26071917","article-title":"Metabolic N-dealkylation and N-oxidation as elucidators of the role of alkylamino moieties in drugs acting at various receptors","volume":"26","author":"Eh-Haj","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119158_bib62","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.2174\/092986712803988820","article-title":"Medicinal chemistry of drugs with active metabolites (N-, O-, and S-desalkylation and some specific oxidative alterations)","volume":"19","author":"Ram","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119158_bib63","doi-asserted-by":"crossref","first-page":"900","DOI":"10.2174\/138920011797470100","article-title":"Regioselective sulfation and glucuronidation of phenolics: insights into the structural basis","volume":"12","author":"Wu","year":"2011","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejmech.2026.119158_bib64","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/cbdv.200900055","article-title":"Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity?","volume":"6","author":"Kalgutkar","year":"2009","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejmech.2026.119158_bib65","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2013.0099","article-title":"The chemistry, physiology and pathology of pH in cancer","volume":"369","author":"Swietach","year":"2014","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"10.1016\/j.ejmech.2026.119158_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116493","article-title":"Distinct cellular uptake patterns of two anticancer unsymmetrical bisacridines and their metabolic transformation in tumor cells","volume":"252","author":"Frackowiak","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2026.119158_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nano11020462","article-title":"Quantum dots as a good carriers of unsymmetrical bisacridines for modulating cellular uptake and the biological response in lung and colon cancer cells","volume":"11","author":"Pilch","year":"2021","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ejmech.2026.119158_bib68","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3390\/ijms23031261","article-title":"Foliate-targeting quantum dots-\u03b2-cyclodextrin nanocarrier for efficient delivery of unsymmetrical bisacridines to lung and prostate cancer cells","volume":"23","author":"Pilch","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119158_bib69","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1039\/C7PY00559H","article-title":"Multicellular tumor spheroids: a relevant 3D model for the in vitro preclinical investigation of polymer nanomedicines","volume":"8","author":"Lazzari","year":"2017","journal-title":"Polym. Chem."},{"key":"10.1016\/j.ejmech.2026.119158_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115780","article-title":"Cellular effects of selected unsymmetrical bisacridines on the multicellular tumor spheroids of HCT116 colon and A549 lung cancer cells in comparison to monolayer cultures","volume":"24","author":"Kulesza","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119158_bib71","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.3390\/molecules28196812","article-title":"In vitro enzyme kinetics and NMR-based product elucidation for glutathione S-conjugation of the anticancer unsymmetrical bisacridine C-2028 in liver microsomes and cytosol: major role of glutathione S-transferase M1-1 isoenzyme","volume":"28","author":"Pot\u0119ga","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119158_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.113970","article-title":"Electrochemical simulation of metabolic reduction and conjugation reactions of unsymmetrical bisacridine antitumor agents, C-2028 and C-2053","volume":"197","author":"Pot\u0119ga","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2026.119158_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115607","article-title":"Electrochemistry\/mass spectrometry (EC\/MS) for fast generation and identification of novel reactive metabolites of two unsymmetrical bisacridines with anticancer activity","volume":"235","author":"Pot\u0119ga","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2026.119158_bib74","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/00498254.2019.1643515","article-title":"Flavin-containing monooxygenase 3 (FMO3): genetic variants and their consequences for drug metabolism and disease","volume":"50","author":"Phillips","year":"2020","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejmech.2026.119158_bib75","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.bcp.2012.08.026","article-title":"Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity","volume":"84","author":"Korprasertthaworn","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119158_bib76","article-title":"Polymorphic expression of UDP-glucuronosyltransferase UGT1A gene in human colorectal cancer","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119158_bib77","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4161\/oxim.3.4.13246","article-title":"Deleterious effects of reactive metabolites","volume":"3","author":"Attia","year":"2010","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejmech.2026.119158_bib78","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1021\/acs.chemrestox.6b00256","article-title":"Formation and biological targets of quinones: cytotoxic versus cytoprotective effects","volume":"30","author":"Bolton","year":"2017","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119158_bib79","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0009-2797(00)00214-3","article-title":"Glutathione conjugation as a bioactivation reaction","volume":"129","author":"van Bladeren","year":"2000","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2026.119158_bib80","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/antiox10050701","article-title":"Glutathione S-transferases in cancer","volume":"10","author":"Singh","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejmech.2026.119158_bib82","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1021\/acs.jpcb.6c01505","article-title":"Reframing triazoloacridinone C-1305 as a G-quadruplex pharmacophore","volume":"130","author":"Paku\u0142a","year":"2026","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ejmech.2026.119158_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2023.130482","article-title":"Insights into the mechanism of binding of doxorubicin and a chlorin compound with 22-mer c-Myc G-quadruplex","volume":"1867","author":"Shukla","year":"2023","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.ejmech.2026.119158_bib86","doi-asserted-by":"crossref","DOI":"10.1002\/jcc.70035","article-title":"Atomistic insights into interaction of doxorubicin with DNA: from duplex to nucleosome","volume":"46","author":"Ned\u011bln\u00edkov\u00e1","year":"2025","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2026.119158_bib81","doi-asserted-by":"crossref","first-page":"6722","DOI":"10.1021\/ja8016973","article-title":"Structural basis of DNA quadruplex recognition by an acridine drug","volume":"130","author":"Campbell","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.119158_bib84","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1021\/acs.jpcb.3c03031","article-title":"Nonselective intercalation of G-quadruplex-targeting ligands into double-stranded DNA quantified by single-molecule stretching","volume":"127","author":"Liu","year":"2023","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ejmech.2026.119158_bib83","doi-asserted-by":"crossref","first-page":"14779","DOI":"10.1021\/jp9066394","article-title":"Shedding light on the interaction between TMPyP4 and human telomeric quadruplexes","volume":"113","author":"Martino","year":"2009","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ejmech.2026.119158_bib87","doi-asserted-by":"crossref","first-page":"9932","DOI":"10.1093\/nar\/gky824","article-title":"Site-specific amino acid substitution in dodecameric peptides determines the stability and unfolding of c-MYC quadruplex promoting apoptosis in cancer cells","volume":"46","author":"Sengupta","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.119158_bib88","doi-asserted-by":"crossref","first-page":"9706","DOI":"10.1021\/bi100509s","article-title":"The C-terminus of nucleolin promotes the formation of the c-MYC G-quadruplex and inhibits c-MYC promoter activity","volume":"49","author":"Gonz\u00e1lez","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2026.119158_bib89","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12943-020-01291-6","article-title":"Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc","volume":"20","author":"Madden","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119158_bib90","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1080\/15257770600809913","article-title":"Structure of the biologically relevant G-quadruplex in the c-MYC promoter","volume":"25","author":"Yang","year":"2006","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.ejmech.2026.119158_bib91","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3390\/biomedicines11030969","article-title":"G-Quadruplexes in c-MYC promoter as targets for cancer therapy","volume":"11","author":"Bahls","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.119158_bib92","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2320240121","article-title":"G-quadruplex DNA structure is a positive regulator of MYC transcription","volume":"121","author":"Esain-Garcia","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2026.119158_bib93","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1038\/s41467-018-06315-w","article-title":"Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex","volume":"9","author":"Calabrese","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119158_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116492","article-title":"Overcoming therapy resistance in pancreatic cancer: new insights and future directions","volume":"229","author":"Espona-Fiedler","year":"2024","journal-title":"Biochem. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:16:31Z","timestamp":1788048991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":94,"alternative-id":["S0223523426006033"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119158","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unsymmetrical bisacridines as anticancer drug candidates: structure\u2013metabolism\u2013activity relationships and design principles","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119158"}}